1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

20 Dec 2019
Admin
News Article

Natco launches cut price versions of cancer drug ibrutinib in india

Hyderabad-based Natco Pharma has launched a cut price version of ibrutinib, an anti-cancer drug, under its own brand name Ibrunat. The patent for the drug is held by Pharmacyclics for three to four more years in India. Pharmacyclics was globally acquired by US giant AbbVie in 2015 in a massive USD21 billion deal. In India, the marketing right for ibrutinib is held by Johnson & Johnson. Ibrutinib is used to treat patients with leukemia and similar other indications of cancer. A Natco official confirmed its launch but refused to divulge more details. It is learnt that the Indian drug maker has already dispatched the drug in distribution channels. The Natco drug will cost at approximately INR 38000 per month as opposed to INR 4 lakh course of the innovator. A patient is expected to take 4 tablets each day. Sources informed ET that Pharmacyclics had filed for an injunction petition in Delhi High Court but no clear decision was handed out. Natco was directed to maintain data for its inventory and stocks sold. Natco's latest move is consistent with its earlier launches and challenging the patents held on anti-cancer drugs by multinational drug companies. In July this year, the Delhi High Court had dismissed an injunction plea by Bayer to halt Natco from selling copies of its brand of regorafenib. Bayer's products in three versions, marketed since 2013 in India, were priced at INR36000 to INR40000 per bottle of 28 tablets, while Natco's product was made available at INR9000 per bottle.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!